| Literature DB >> 29444602 |
Lara Hilton1,2, Pamela Elfenbaum1, Shamini Jain3, Meredith Sprengel1, Wayne B Jonas1.
Abstract
BACKGROUND: The evaluation of freestanding integrative cancer clinical programs is challenging and is rarely done. We have developed an approach called the Claim Assessment Profile (CAP) to identify whether evaluation of a practice is justified, feasible, and likely to provide useful information.Entities:
Keywords: Claims Assessment Profile; cancer research; complementary and integrative cancer evaluation; evaluability assessment; optimal healing environment
Mesh:
Year: 2016 PMID: 29444602 PMCID: PMC5950945 DOI: 10.1177/1534735416684017
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Figure 1.InspireHealth logic model.
Patient Characteristics at Time of Evaluation (N = 588).
| Demographics | n | % |
|---|---|---|
| Referral type | ||
| Word of mouth | 347 | 59% |
| Family members | 106 | 18% |
| Referring providers | 53 | 9% |
| Clinic staff | 41 | 7% |
| Website | 29 | 5% |
| Advertisement | 12 | 2% |
| Gender | ||
| Female | 392 | 67% |
| Male | 196 | 33% |
| Age (years) | ||
| >17 | 0 | 0% |
| 17-44 | 123 | 21% |
| 45-64 | 353 | 60% |
| 65 and older | 112 | 19% |
Cancer Diagnoses for Current Patient Caseload During Evaluation Period (N = 588).
| Cancer Type | n | % |
|---|---|---|
| Breast | 192 | 32.7% |
| Colon | 48 | 8.2% |
| Prostate | 38 | 6.5% |
| Lung | 35 | 6.0% |
| Skin | 22 | 3.7% |
| Rectum | 21 | 3.6% |
| Brain | 17 | 2.9% |
| Leukemia | 17 | 2.9% |
| Urinary | 17 | 2.9% |
| Ovarian | 16 | 2.7% |
| Pancreas | 15 | 2.6% |
| Oropharynx | 14 | 2.4% |
| Thyroid | 10 | 1.7% |
| Multiple myeloma | 9 | 1.5% |
| Non-Hodgkin’s lymphoma | 9 | 1.5% |
| Stomach | 9 | 1.5% |
| Bladder | 8 | 1.4% |
| Hodgkin’s lymphoma | 8 | 1.4% |
| Lymphosarcoma | 8 | 1.4% |
| Uterus | 7 | 1.2% |
| Esophagus | 6 | 1.0% |
| Other types of cancer[ | 62 | 10.5% |
Other cancers include <1% of patients presenting with the following diagnoses: adenoid cystic, bile duct, biliary tract, bone, cervix, chronic lymphocytic leukemia, eye, gallbladder, kidney, larynx, liver, myelodysplastic syndromes, neuroendocrine, NH lymphoma, peritoneum, synovial sarcoma, testicle, tongue, tonsils, trachea, vulva cancer.
Figure 2.InspireHealth causal path model.